Calman A. MacLennan
BM, BCh, DPhil, FRCP, FRCPath
Professor of Vaccine Immunology (University of Birmingham)
- MRC Senior Clinical Fellow, Jenner Investigator and Group Leader - Gonococcal Vaccine Project, Jenner Institute
- Senior Program Officer - Bacterial Vaccines; Lead - Shigella Portfolio & Salmonella Vaccines Product Development, Global Health - Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation
- Director, BactiVac Bacterial Vaccinology Network; Professor of Vaccine Immunology, University of Birmingham
- Consultant Immunologist, Oxford University Hospitals NHS Trust
My main research objective is to understand the immunological basis of protection against invasive bacterial disease with a view to prevention and treatment, focusing on communities in resource-limited settings and patients with impaired immunity. My programme at the Jenner Institute aims to combine improved understanding of naturally-acquired immunity and vaccine-induced immunity to invasive bacteria, focusing on Salmonella, with a view to the development of effective and affordable vaccines against these pathogens for use in the developing world. This work involves partnership and collaboration with sites in low-income countries and exploitation of effective and affordable vaccine technologies, such as Generalized Modules for Membrane Antigens (GMMA).
Key publications
-
Rapid transcriptional responses to serum exposure are associated with sensitivity and resistance to antibody-mediated complement killing in invasive Salmonella Typhimurium ST313
Journal article
Ondari EM. et al, (2019), Wellcome Open Research, 4, 74 - 74
-
How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
Journal article
Giersing BK. et al, (2019), Vaccine, 37, 4778 - 4783
-
Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella.
Journal article
Micoli F. et al, (2018), Proc Natl Acad Sci U S A, 115, 10428 - 10433